Portfolio Companies Introduction
Badge Text Happy Card Title Happy card description goes here Button Text
Dizlin Pharmaceuticals AB
Dizlin Pharmaceuticals AB is a Swedish research-based pharmaceutical company dedicated to developing innovative treatments for advanced stages of Parkinson disease. Collaborating with the University of Gothenburg and Linköping University, Dizlin has developed two key products: Infudopa SubC™ Infudopa IntraV™
Barnik Holdings
Barnik Holdings serves as the holding company for all our portfolio companies, consolidating our investments and streamlining operations to foster growth and innovation across the life science sector.
Curovir
Curovir is a privately held Swedish SME, fully owned by Claesson and Anderzén Group, a family office, with its business divided into real estate and other investments. Curovir is a virtual organisation optimized for flexibility to meet needs as they appear.
Longevience AB
AgeViva promotes anti-aging and longevity A cutting-edge dietary supplement from yeast cells Reduces inflammation and oxidative stress Supports brain and nerve growth factors It has Anti-parkinsonian effects Longevity is of interest for the traditional pharma industry. The longevity market estimates an annual growth rate (CAGR) of 22.2 %. The combined markets for Longevity and diseases such as Type 2 diabetes that can be treated with longevity drugs was $127B in 2021.
Milmed
Milmed is a patented method and a health-promoting agent based on 15 years of research into specially treated yeast cultures. The current patented therapeutic areas, all with the same technology and product, include inflammatory conditions, allergies, and neurodegenerative disorders. The company’s product is now marketed as a food supplement, alnozine.com (with focus on allergies), but it is also on the journey of being registered as a medicinal product for the treatment of IBS.
Colzyx
Colzyx utilizes human peptides shaped by evolution in state-of-the-art wound care products, harnessing the power of native collagen-based technology to promote rapid tissue repair. Colzyx offers a non-cytoxic solution for challenging tissue disruptions, promoting cellular growth while at the same time preventing bacterial growth –products that also lessen the need for using antibiotics.